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Abstract The aim of the present study is to identify microRNAs (miRs) with high potential to be used as biomarkers in plasma
and/or serum to clinically diagnose, or provide accurate prognosis for survival in, patients with atherosclerosis, coron-
ary artery disease, and acute coronary syndrome (ACS). A systematic search of published original research yielded a
total of 72 studies. After review of the risk of bias of the published studies, according to CochraneCollaboration and the
QUADUAS Group standards, 19 studies were selected. Overall 52 different miRs were reported. In particular, miR-
133a/b (5 studies), miR-208a/b (6 studies), and miR-499 (7 studies) were well studied and found to be significant diag-
nostic and/or prognostic markers across different cardiovascular disease progression stages. miR-1 and miR-145b are
potential biomarkers of ACS; miR-1 with higher sensitivity for all acute myocardial infarction (AMI), and miR-145 for
STEMI and worse outcome of AMI. But when miRs were studied across different ACS study populations, patients had
varying degrees of coronary stenosis, which was identified as an important confounder that limited the ability to quan-
titatively pool the study results. The identified miRs were found to regulate endothelial function and angiogenesis (miR-
1, miR-133), vascular smooth muscle cell differentiation (miR-133, miR-145), communication between vascular smooth
muscle and endothelial cell to stabilize plaques (miR-145), apoptosis (miR-1, miR-133, miR-499), cardiac myocyte dif-
ferentiation (miR-1, miR-133, miR-145, miR-208, miR-499), and to repress cardiac hypertrophy (miR-133). Their role in
these processes may be explained by regulation of shared RNA targets such as cyclin-dependent kinase inhibitor 1A (or
p21), ETS proto-oncogene 1, fascin actin-bundling protein 1, hyperpolarization-activated cyclic nucleotide-gated potas-
sium channel 4, insulin-like growth factor 1 receptor LIM and SH3 protein 1, purine nucleoside phosphorylase, and
transgelin 2. These mechanistic data further support the clinical relevance of the identified miRs. miR-1, miR-133a/b,
miR-145, miR-208a/b, and miR-499(a) in plasma and/or serum show some potential for diagnosis of cardiovascular dis-
ease. However, biased selection of miRs in most studies and unexplained contrasting results are major limitations of
current miR research. Inconsistencies need to be addressed in order to definitively identify clinically useful miRs. There-
fore, this paper presents important aspects to improve future miR research, including unbiased selection of miRs, stand-
ardization/normalization of reference miRs, adjustment for patient comorbidities and medication, and robust protocols
of data-sharing plans that could prevent selective publication and selective reporting of miR research outcomes.
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1. Introduction
MicroRNAs (miRs) are endogenous, non-coding, and small (18–22 nu-
cleotides) RNA molecules. miRs are recruited to the RNA-induced
silencing complex (RISC) and regulate the output of protein-coding
genes through diverse mechanisms.1 The interaction of miRs with the
3′ untranslated region (3′ UTR) of protein-coding genes is considered
as the main mechanism, which usually leads to a decrease in protein
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output either by mRNA degradation or by translational repression.2
Recent studies have also suggested that miRs can interact with the 5′
UTR of protein-coding genes via complementarity and cause transla-
tional repression3 or activation of the targeted proteins.4 Similarly,
miRs can also target the coding sequence and repress the translation
of targeted genes.5 Moreover, some miRs can interact with regulatory
protein complexes, such as argonaute 2 and fragile X mental
retardation-related protein 1, and indirectly up-regulate the translation
of a target gene.6 miRs are produced by all cell types, and the same miR
may be derived from a variety of cell sources, such as endothelial cells,
monocytes and macrophages, vascular smooth cells, and platelets and
eventually are secreted in blood. There, degradation may be circum-
vented by being packaged in microparticles (exosomes, microvesicles,
and apoptotic bodies) or bound with proteins or high-density lipopro-
teins (HDLs).7–9 In this publication, all miRs detected in plasma or ser-
um are reviewed, independent of their cell origin or their package in
microparticles and/or lipoproteins.
Several miRs were shown to take part in the pathogenesis of coron-
ary artery disease (CAD)10,11 and atherosclerosis.12–14 Therefore, we
aim to determine whether miRs in plasma and/or serum differentiate
between stable and unstable CAD (or acute coronary syndromes;
ACSs), unstable angina (UA) or acute myocardial infarction (AMI) with-
in ACS, STEMI, or non-STEMI AMI, or are markers of worse outcome
such as (cardiac) death. In preparing this review, the authors followed
current guidance on producing high-quality systematic reviews and
meta-analyses of diagnostic test accuracy, by both the Cochrane Col-
laboration15 and the QUADUAS Group.16 As per the Cochrane Col-
laboration,17 when studies that lackmethodological rigor or have a high
risk of bias are combined in a meta-analysis, the uninformative or erro-
neous results can lead to wasting further resources on future research
or can even lead to harm if patients are wrongly diagnosed. The authors
also followed the PRISMA18 reporting guidelines for systematic reviews
(see Supplementary material online, File S1). In following these stan-
dards, we aimed at providing quality evidence for the rational choice
of miRs to focus on in future research, identifying the miRs with high
potential for clinical applicability to distinguish patients with the disease
from those without. In the second and third parts of this review, we
searched for and report on mechanistic data on the clinical relevance
and on the target genes of miRs with high potential identified in the first
part of our study.
2. Methods
2.1 Information resources, search, and study
selection
The strategy and outcome of the literature search are illustrated in Figure 1.
We searched the PubMed database for English language articles related
to miRs as biomarkers in atherosclerosis, CAD, and ACS in humans, with
the last search taking place on 7 October 2015. No lower date limit was
used. The search strategy was performed by two independent researchers
(D.G. and R.N.), encompassing a MESH search: (‘Coronary Artery Disease’
[Mesh] OR ‘Atherosclerosis’[Mesh] OR ‘Myocardial Infarction’[Mesh] OR ‘Acute
Coronary Syndrome’[Mesh]) AND (‘MicroRNAs’[Mesh]) AND (Humans
[Mesh] and English[lang]), identifying 412 titles. As well, a second more
extended search of typical keywords was performed using: ((mir OR Micro-
RNA) NOT (mir[author])) AND (atherosclerosis OR CAD OR ACS OR myocar-
dial infarction) and (plasma OR serum OR blood OR circulating OR circulation)
AND (Humans[Mesh] and English[lang]) NOT (Review[Publication Type]).
This text search resulted in the identification of 259 articles: with 201
articles being duplicates of the MESH search strategy and 58 new unique
articles. In addition, 17 articles were identified from reference lists and au-
thor archives. From the 487 unique articles, a title screen was performed by
three authors (R.N., D.G., and P.H.), and articles were excluded based on
the following criteria:
† Experiments in molecular biology/biochemistry (n ¼ 75),
† Experiments in pharmacology (n ¼ 23),
† miR examined in cells or tissues other than blood (n ¼ 30),
† Medical field other than cardiology (n ¼ 56),
† Topic out of scope (though cardiology) (n ¼ 84),
† Experiments with laboratory animals (n ¼ 14),
† Other experiments in genetics (n ¼ 23),
† Article is a review, editorial, comment, or interview, not an original re-
search article (n ¼ 64),
† Target population out of scope (n ¼ 3).
Title screening left a total of 115 papers, which were then screened by ab-
stract. The exclusion criteria were as follows:
† Experiments in molecular biology/biochemistry (n ¼ 4),
† Experiments in pharmacology (n ¼ 1),
† miR examined in cells or tissues other than blood (n ¼ 4),
† Medical field other than cardiology (n ¼ 1),
† Topic out of scope (though cardiology) (n ¼ 3),
† Experiments with laboratory animals (n ¼ 1),
† Other experiments in genetics (n ¼ 4),
† Article is a review, editorial, comment, or interview, not an original re-
search article (n ¼ 25).
After abstract screening, 72 original research papers remained as being po-
tentially relevant to this review. Of these, 3 papers were not obtainable, leav-
ing 69 papers for full review. Data were extracted from each paper into an
excel sheet, recording the main methods, results (up/down-regulation of
miRs by outcome), and assessment of risk of bias, as described below.
2.2 Assessment of risk of bias for analysis and
pooling of study results
Studies identified to be within the scope of this review where assessed for
risk of bias by R.N., P.H., and D.G. A recent review of bias,19 as well as the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accur-
acy,17,20,21 reports that there is consistent evidence of bias, with studies
using a case-control design reporting higher accuracy of tests when com-
pared with a cohort design. They also report a consistent association be-
tween the study outcome and the use of inappropriate reference
standards or the biased recruitment of patients. The QUADAS-2 tool to
assess quality of studies also highlights the potential bias inherent in the
case-control design, patient recruitment, and use of reference standard.16
For this review, the study design, patient selection, miR index test, and ref-
erence standard were the main aspects scrutinized for risk of bias for each
outcome of interest. In addition, to study the potential risk of bias across
studies, data were collected on how miRs were selected for each study
and on all miRs reported to have been studied, to be able to compare
and contrast negative and positive results across all studies, and to identify
potential bias in the selection and selective reporting of miRs studied. Dis-
agreements on risk of bias for individual studies were discussed and a final
assessment made through consensus between these three authors. Pooling
of results was planned for studies with the lowest potential for bias and for
studies that were sufficiently homogeneous based on miR and disease being
examined.
2.3 Mechanistic data of role of miRs in
progression of cardiovascular diseases
A comprehensive search of the literature was undertaken for studies that
presented data on the role of the miRs that were most studied and had the
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most significant associations identified in this review. The last search was
undertaken in PubMed on 12 February 2012 and included the following
search terms:
(MicroRNAs[Mesh]) AND (‘Coronary Artery Disease’[Mesh] OR ‘Ather-
osclerosis’[Mesh] OR ‘Myocardial Infarction’[Mesh] OR ‘Acute Coron-
ary Syndrome’[Mesh])
AND
((miR-1 OR miR-133 OR miR-133a OR miR-133b OR miR-145 OR
miR-208 OR miR-208a OR miR-208b OR miR-499 OR miR-499a)
NOT (mir[author]))
The mechanistic studies were reviewed and mechanisms related to cardio-
vascular disease progression described in the results section.
2.4 Target search
To better understand the relation between miRs and their function, we
screened mirtarbase database for their RNA targets. We limited RNA spe-
cies for Homo sapiens for which data were validated by reporter assay
analysis, qPCR, and western blot analysis were available. We looked for
shared targets to suggest common pathways.
3. Results
3.1 Part 1: clinical data on diagnostic
potential
Overall, out of the 69 papers reviewed in full, 19 studies22–40 were se-
lected as having sufficient quality to assess the value of the miRs as po-
tential biomarkers for cardiovascular disease. Data extracted from the
included, missing,41–43 and excluded studies, with an appropriate study
design but insufficient quality11,44–65 and with a less reliable study de-
sign and insufficient quality,66–92 are available in Supplementary mater-
ial online, File 2.
Due to the heterogeneity between included studies, in the study po-
pulations, settings, miRs and outcomes investigated, quantitative
Figure 1 Flow diagram from study identification to inclusion.
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pooling of study results was deemed inappropriate, and therefore a
qualitative summary by miRs and disease outcome/progression is pre-
sented below. Due to lack of clarity in the results of the groups com-
pared and results presented in Li (2015),29 this study was not included
in the summaries below.
3.1.1 Non-CAD vs. CAD
Six original studies24–26,32,33,40 (Table 1) investigated miRs and their va-
lue in distinguishing between CAD and non-CAD patients, questioning
the need for recurrent diagnostic imaging.
miR-133a,24,33 miR-134, miR-145,25 miR-122, and miR-37026
were associated with CAD presence, even after adjustment for
other cardiovascular risk factors. Furthermore, their levels were
positively correlated with the severity of CAD quantified by the
Gensini score, in other words, may be used to predict both the
presence and severity of coronary lesions in CAD patients. A single
study reported miR-15540 being associated inversely with compli-
cated pro-atherogenic metabolic risk factors. In separate studies,
miR-126,32 miR-33a/b26 as well as miR-1, miR-16, miR-122, miR-
208b, miR-375, and miR-49924 were not significantly down-
regulated or up-regulated in CAD patients and so not suitable for
discriminating CAD patients from patients without CAD.
3.1.2 Stable CAD vs. ACS
Three studies selected miRs to more accurately define stable CAD and
ACS25,31,37 (Table 2). miR-1, miR-21, and miR-49931 proved to add to
the diagnostic value of high-sensitive troponin (hs-Tn), a marker of car-
diac injury, or in some cases be a better diagnostic biomarker than
hs-Tn. miR-1, miR-499, and miR-21 significantly increased the diagnos-
tic value in all suspected ACS patients, independent of clinical
co-variants, including patient history and cardiovascular risk factors.
All these miRs together with miR-14525 were found to be associated
with the severity of CAD. However, the biggest prognostic or
diagnostic value was obtained with the combination of miR-132,
miR-150, and miR-186,37 even when compared with combined four
classical biomarkers hsTnI, BNP, C-reactive protein (C-REACTIVE
PROTEIN), and cystatin C.
3.1.3 Acute chest pain/UA vs. AMI
The major aim of five studies22,34–36,38 (Table 3) was to identify super-
ior diagnostic and prognostic markers for more accurate and timely
diagnosis of UA and AMI. With the highest accuracy, miR-208a/
b22,34,35 stood out as the early detectable specific diagnostic marker
of AMI when compared with cTnI or hs-cTnT. miR-133a,34,35
miR-320a,22 and miR-49922,34,38 also proved to be sensitive and specific
AMI diagnostic biomarkers. In contrast, two studies of miR-45122,34 and
single studies of miR-499,35 miR-320,36 andmiR-1634 showed no signifi-
cant differences in the regulation of these miRs between comparison
groups. A single population study investigated 18 miRs, with the results
suggesting that only miR-126, miR-223, and miR-19736 are associated
with AMI disease risk. However, miR-126 and miR-197 were not tested
in any of the other four studies and one other study questioning the
finding of miR-223,22 as they reported not having a significant difference
in regulation between UA and AMI.
3.1.4 Non-STEMI vs. STEMI
Five of the studies also investigated the ability to detect differences in
levels of miRs between patients with Non-STEMI vs. STEMI22,24,25,35,39
(Table 4). Previously described as potential AMI diagnostic markers,
miR-133a, miR-208b,22,35 as well as miR-499 and miR-451,22 and
miR-13424 levels were reported as higher in STEMI, when compared
with non-STEMI. In contrast, two studies of miR-49924,35 showed no
significant difference in miR expression. A combination of miR-486
and miR-15039 was reported to be sensitive and specific for the dis-
crimination of non-STEMI cases from non-AMI controls, but not for
discriminating non-STEMI from STEMI. It can be noted that STEMI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Overview of significant miRs identified in all included studies, organized by disease progression: non-CAD vs. CAD
Study Number of patients Tested miRs Significant miRs Statistical analysis
Gacon´ et al.24 16 (2); 27 (+)a miR-1, miR-16, miR-34a, miR-122,
miR-124, miR-133a/b, miR-134,
miR-208b, miR-375, miR-499
miR-34a, miR-124, miR-133a/b,
miR-134 (+)
Unadjusted non-parametric
Kolmogorov–Smirnov testb,c:
miR-124 (P, 0.025); others (P, 0.05)
Gao et al.25 28 (2); 167 (+) miR-145 miR-145 (2) Multivariate linear regressiond:
P, 0.0001
Gao et al.26 100 (2); 155 (+) miR-33a/b, miR-122, miR-370 miR-122, miR-370 (+) Multivariate linear regressiond:
miR-122 (P ¼ 0.034); miR-370 (P¼ 0.022)
Sun et al.32 36 (2); 31(+) miR-126 – Unadjusted Mann–Whitey U or
Kruskal–Wallis testb: P ¼ 0.675
Wang et al.33 92 (2); 154 (+) miR-133a miR-133a (+) Multivariate linear regressiond: P, 0.001
Zhu et al.40 54 (2); 56 (+) miR-155 miR-155 (2) Unadjusted Student’s t-teste: P, 0.001
Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.
Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified
for each study separately.
aPatent IRA vs. occluded IRA.
bPatient characteristics: no significant differences for traditional risk factors and biomarkers.
cROC AUC values are also available in the SF2 Study Quality table.
dAdjusted for traditional risk factors.
eNo significant difference in traditional risk factors and medications taken, but significant difference in high-sensitivity C-reactive protein. However, miR-155 was not independent of age,
hypertension, total C, HDL-C, LDL-C, high-sensitivity C-reactive protein, and smoking.
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patients had significantly lower miR-145,25 compared with the other
groups indicating an altered expression of miR-145 in these patients.
In contrast, miR-223 and miR-320a,22 as well as miR-1,24,35 and 7 add-
itional miRs24 provided no added diagnostic value for discriminating be-
tween non-STEMI and STEMI patients when combined with cTnT or
hs-cTnT.
3.1.5 Mortality
The seven selected studies22,23,27,28,30,35,36 (Table 5) did not identify
miRs which significantly predicted long-term mortality; however, mid-
term and short-term mortality could be predicted to a certain extent.
miR-208b22,35 is one of few significant mortality predicting biomar-
kers, which remained significant after adjustment for age and gender.
miR-133a35 levels were significantly related to all-cause mortality,
with a single study reporting a 2.5-fold higher risk of death in the fourth
quartile compared with patients in the first three quartiles (P ¼ 0.011).
It remained significant after adjustment for age and gender, but not after
further adjustment for hs-TnT levels on admission. However, in con-
trast, another study found no difference in expression for
miR-208b27 or miR-133a.22
miR-32828 was found to increase in patients who experienced heart
failure or death within 6 months in the only study testing this miR. In
contrast, miR-13428,30 andmiR-22322,36 were investigated in two differ-
ent studies each with opposing results in terms of miR expression.
All three studies testing miR-49922,27,35 and two studies testing
miR-93,30,36 miR-320,22,36 or miR-45122,35 found no significant differ-
ence in expression in those that survived vs. those that died. In addition,
22 other miRs were tested once and did not show any difference in le-
vel of their expression between comparison groups.
3.2 Cardiovascular disease progression
Some miRs, including miR-133a/b (5 studies22,24,33 – 35), miR-208a/b
(6 studies22,24,27,31,34,35), and miR-499 (7 studies22,24,27,31,34,35,38) have
been well studied and found to be significant diagnostic and/or prog-
nostic markers across different cardiovascular disease progression
stages (Table 6), in most studies outperforming cTnT or hs-cTnT.
miR-1 is a potential biomarker of ACS, with higher sensitivity for
AMI.31,34,35 Another potential biomarker of ACS is miR-145,23,26
with higher sensitivity for STEMI and worse outcome of AMI.
Mid- and short-term mortality prediction was reported, with con-
trasting results for miR-133a22,35 and miR-208b.22,27,35
No firm conclusions about the potential diagnostic value of miR-21,31,36
miR-126,32,36miR-134,24,28miR-146a/b,31,36miR-150,36,37,39 andmiR-48639
can be drawn because of lack of studies across different cardiovascular dis-
ease progression stages and contrasting results between studies. In contrast
tomiRs which were found to be associatedwith one ormore stages in car-
diovascular disease progression,miR-122was found to be non-specific in all
studies,24,26,36 as were miR-16,24,34 miR-223,22,36 and miR-320(a).22,36
3.3 Part 2: mechanistic data of role of miRs
in progression of cardiovascular diseases
After review for relevance by two study authors (P.H. and R.N.), the
studies presenting mechanistic data are described below. We searched
mechanistic data for miRs with significant associations across different
cardiovascular disease progression states and therefore have the high-
est potential as biomarkers. Several other recent reviews have dis-
cussed roles of miRs in atherosclerosis and cardiovascular
diseases.14,93–99 Functions of miRs are summarized in Figure 2.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Overview of significant miRs identified in all included studies, organized by disease progression: stable CAD vs. ACS
Study Number of
patients
Tested miRs Significant miRs Statistical analysis
Gao et al.25 26 (2); 141(+)a miR-145 miR-145 (2) Multivariate linear regressionb: P, 0.005
Oerlemans
et al.31
226 (2); 106 (+)c miR-1, miR-21, miR-146a,
miR-208a, miR-499
miR-1, miR-21, miR-146a,
miR-208a, miR-499 (+)
Multivariate logistic regression (OR: 95% CI)b,d,e:
miR-1 (1.30: 1.17–1.42);
miR-21 (1.28: 1.18–1.39);
miR-146a (1.14:1.08–1.21); miR-208a (1.16:1.03–1.30);
miR-499 (1.28:1.18–1.40)
Zeller et al.37 48 (2); 49 (+) miR-19a/b, miR-132,
miR-140-3p, miR-142-5p,
miR-150, miR-186,
miR-210
miR-19a/b, miR-132,
miR-140-3p, miR-142-5p,
miR-150, miR-186,
miR-210
Unadjusted Mann–Whitney testf,e:
miR-19a/b (P ¼ 0.003);
miR-132 (P ¼ 0.005);
miR-140-3p (P ¼ 0.002);
miR-142-5p (P ¼ 0.001);
miR-150 (P, 0.00001);
miR-186 (P ¼ 0.007);
miR-210 (P, 0.0002)
Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.
Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified
for each study separately.
aUA and non-STEMI combined.
bAdjusted for traditional risk factors.
cTwenty-four UA and 82 non-STEMI combined.
dAlso adjusted for family and CVD history and cardiac hs-troponin T; overall, miR-1+ miR-499 + miR-21 showed the highest discriminatory power after adjustment (AUC ¼ 0.94; 95% CI:
0.92–0.97).
eROC AUC values are also available in the SF2 Study Quality table.
fPatients randomly selected from larger cohort studies and patient characteristics found comparable; miR-132, miR-150, andmiR-186 showed the highest discriminatory power in validation
(46 UA; 63 CAD patients) using logistic regression (AUC ¼ 0.91; 95% CI: 0.84–0.98).
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miR-1 prevented endothelial permeability in apoE KO mice100 and
induced angiogenesis by repressing mRNA encoding seryl-tRNA
synthetase.101 Its effect on angiogenesis was opposite to that of
miR-206.101,102 In addition, miR-1-transfected embryonic stem cell en-
hanced cardiac myocyte differentiation and inhibited apoptosis by
modulating the PTEN/Akt pathway in the infarcted heart.103 miR-1 ex-
pression depended on SERCA2. Indeed, SERCA2a gene therapy of fail-
ing hearts restored miR-1 expression by an Akt/FoxO3A-dependent
pathway, which is associated with normalized expression of sodium–
calcium exchanger 1 (NCX) resulting in improved cardiac function.104
miR-133 suppressed angiogenesis properties of endothelial cells
such as proliferation rate, cell viability, and migration activity by target-
ing VEGFR2 and FGFR1.105 miR-133 decreased when vascular smooth
muscle cells (VSMCs) were primed to proliferate in vitro and following
vascular injury in vivo, whereas it increased when VSMCs were coaxed
back to quiescence in vitro and in vivo. miR-133 loss- and gain-of-function
experiments showed that miR-133 plays a mechanistic role in VSMC
growth. Accordingly, adeno-miR-133 reduced but anti-miR-133 exa-
cerbated VSMC proliferation and migration in vitro and in vivo, by sup-
pressing the transcription factor Sp-1 expression.106 miR-133 and
miR-1, which belong to the same transcriptional unit, were decreased
in mouse and human models of cardiac hypertrophy. In vitro overex-
pression of miR-133 or miR-1 inhibited cardiac hypertrophy. In
contrast, suppression of miR-133 by ‘decoy’ sequences induced hyper-
trophy. In vivo inhibition of miR-133 by a single infusion of an antagomir
caused marked and sustained cardiac hypertrophy. RhoA, a GDP–GTP
exchange protein regulating cardiac hypertrophy; Cdc42, a signal trans-
duction kinase implicated in hypertrophy; and Nelf-A/WHSC2, a nu-
clear factor involved in cardiogenesis were identified as specific
targets of miR-133.107
miR-145 and miR-143 were found to be co-transcribed in multipo-
tent mouse cardiac progenitors before becoming localized to smooth
muscle cells; including neural crest stem cell-derived VSMCs. miR-145
and miR-143 were down-regulated in injured or atherosclerotic vessels
containing proliferating, less differentiated smoothmuscle cells. Restor-
ation of miR-145 in balloon-injured arteries via adenovirus miR-145 in-
hibited neointimal growth by inducing VSMC differentiation marker
genes such as SM alpha-actin and calponin by up-regulating Kruppel-like
factor (KLF)-5 and its downstream signalling molecule, myocardin.
Transient decrease in miR-145 expression 3 days post-myocardial in-
farction (MI) was associated with an increase in KLF-5 and a decrease
in myocardin. In vivo delivery of a miR-145 antagomir 1 day prior to and
2 and 6 days after MI, suppressed expression of KLF5 protein, de-
creased myofibroblast formation, and increased scar size.108 miR-145
was necessary for myocardin-induced reprogramming of adult fibro-
blasts into smooth muscle cells and sufficient to induce differentiation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Overview of significant miRs identified in all included studies, organized by disease progression: acute chest pain/UA
vs. AMI
Study Number of
patients
Tested miRs Significant miRs Statistical analysis
Devaux
et al.22
931 (2); 224 (+) miR-133a, miR-208b, miR-223,
miR-320a, miR-451, miR-499
miR-208b, miR-320a,
miR-499 (+)
Unadjusted Mann–Whitey U or Kruskal–Wallis testa,b:
miR-208b (P, 0.001);
miR-320a (P ¼ 0.031);
miR-499 (P, 0.001)
Wang et al.34 33 (2); 33 (+) miR-1, miR-16, miR-133a, miR-208a,
miR-451, miR-499
miR-1, miR-133a,
miR-208a, miR-499 (+)
Unadjusted ROC (AUC: 95% CI)c:
miR-1 (0.85: 0.75–0.94); miR-133a (0.87: 0.77–0.96);
miR-208a (0.97: 0.92–1.00); miR-499 (0.82: 0.72–
0.93)
Widera
et al.35
117 (2)d; 327 (+) miR-1, miR-133a/b, miR-208a/b,
miR-499
miR-1, miR-133a,
miR-208b (+)e
Unadjusted Mann–Whitey U testf,d:
miR-1 (P, 0.001);
miR-133a (P, 0.001);
miR-208b (P ¼ 0.044)
Zampetaki
et al.36
773 (2)e; 47 (+) miR-7b/e, miR-21, miR-24, miR-25,
miR-28-3p, miR-93, miR-122,
miR-126, miR-140, miR-146b,
miR-150, miR-191, miR-197,
miR-223, miR-320, miR-342-3p,
miR-454, miR-486
miR-126 (+); miR-197,
miR-223 (2)
Multivariate Cox regression (HR: 95% CI)g,e:
miR-126 (2.69: 1.45–5.01,
P ¼ 0.002);
miR-197 (0.56: 0.32–0.96,
P ¼ 0.036);
miR-223 (0.47: 0.29–0.75,
P ¼ 0.002)
Zhang L
et al.38
85 (2); 142 (+) miR-499 miR-499 (+) Unadjusted ROC (AUC: 95% CI)f:
0.86: 0.81–0.91
Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.
Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified
for each study separately.
aSeveral significant differences in traditional risk factors; also miRs no longer significant predictors when multivariate regression included troponins.
bROC AUC values are also available in the SF2 Study Quality table.
cPatient traditional risk factors comparable, but significant difference in HDL and WBC.
dOnly UA patients, but large clinical overlap between UA and AMI.
ePopulation-based study: all adults ≥40 years; and adjusted for CVD history, other miRs, waist-to-hip ratio, C-reactive protein, and fibrinogen.
fPatient characteristics: significant differences between traditional risk factors not presented/reported for these patient groups.
gAdjusted for traditional risk factors and biomarkers.
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of multipotent neural crest stem cells into VSMCs. Furthermore,
miR-145 and miR-143 cooperatively targeted a network of transcrip-
tion factors, including KLF-4, myocardin, and ELK1, a member of ETS
oncogene family, to promote differentiation and repress proliferation
of smooth muscle cells. These findings demonstrated that miR-145
can direct the smooth muscle fate and that miR-145 and miR-143
function to regulate the quiescent vs. proliferative phenotype of
smooth muscle cells.109 In addition, miR-145 and miR-143 act as com-
munication molecules between smooth muscle and endothelial cells to
enhance the angiogenic and vessel stabilization properties of endothe-
lial cells.110 Angiotensin II111,112 down-regulated miR-145 and reduced
KLF4 and myocardin expression in human coronary arterial smooth
muscle cells. Overexpression of miR-145 and treatment with valsartan
reversed KLF4 and myocardin protein expression and improved
vascular injury induced by balloon injury. Mechanical stretch sup-
pressed miR-145 expression by activating extracellular signal-regulated
kinase 1/2 and up-regulating angiotensin-converting enzyme to
alter VSMC phenotype, with reduced expression of contractile mar-
kers. Moreover, transcoronary gradients of miR-145-5p, and of
miR-126-3p, correlated with the extent of thin-cap fibroatheromas
suggesting that instable plaques may affect the local uptake or degrad-
ation of these miRs.113
Data discussed above suggested a protective effect of miR-145, but
other studies suggested an opposite effect. Indeed, miR-143/145 defi-
ciency per se resulted in increased hepatic and vascular ABCA1 expres-
sion and significant reduction of atherosclerosis.114 Moreover,
down-regulation of miR-145 protected against the development of pul-
monary arterial hypertension (PAH). In patient samples of heritable
PAH and idiopathic PAH, miR-145 is expressed in remodelled vessels
and mutations in BMPR2 lead to up-regulation of miR-145 in mice and
PAH patients.115
AmiR-208–Mef2 axis was found to drive the decompensation of right
ventricular function in pulmonary hypertension. miR-208 inhibition, as
well as tumour necrosis factor-a, activated the complex mediator of
transcription 13/nuclear receptor co-repressor 1 axis, which in turn pro-
moted Mef2 inhibition, closing a self-limiting feedback loop, driving the
transition from compensating phase of right ventricle hypertrophy to-
wards de-compensation phase.116 Analysis of mice lacking miR-208a in-
dicated that miR-208a was required for proper cardiac conduction and
expression of the cardiac transcription factors homeodomain-only pro-
tein and GATA4 and the gap junction protein connexin 40.117
Heart function was restored in rodents by reprogramming non-
myocytes into cardiomyocytes, by expressing transcription factors
[GATA4, HAND2, myocyte-specific enhancer factor 2C (MEF2C), and
T-box 5 (TBX5)] andmiRs (miR-1, miR-133, miR-208, andmiR-499) that
control cardiomyocyte identity. Stimulating cardiomyocyte dedifferenti-
ation and proliferation by activating mitotic signalling pathways involved
in embryonic heart growth represents a complementary approach for
heart regeneration and repair.118 miR-499 played an inhibiting role in
the mitochondrial apoptosis pathway and had protective effects against
H2O2-induced injury in cardiomyocytes.
119
3.4 Part 3: RNA targets of miRs in
progression of cardiovascular diseases
In addition, we searched targets for these miRs which could give us fur-
ther information about mechanistic action and potential additive effects
of some miRs by sharing target RNA species. Supplementary material
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Table 4 Overview of significant miRs identified in all included studies, organized by disease progression: non-STEMI vs. STEMI
Study Number of
patients
Tested miRs Significant miRs Statistical analysis
Devaux
et al.22
179(2); 45(+) miR-133a, miR-208b, miR-223,
miR-320a, miR-451, miR-499
miR-133a, miR-208b, miR-451,
miR-499 (+)
Unadjusted Mann–Whitey U or Kruskal–Wallis
testa:
miR-133a (P ¼ 0.004);
miR-208b (P ¼ 0.001);
miR-499 (P ¼ 0.001);
miR-451 (P ¼ 0.44)
Gacon
et al.24
27 (2); 16 (+) miR-1, miR-16, miR-34a, miR-122,
miR-124, miR-133a/b, miR-134,
miR-208b, miR-375, miR-499
miR-134 (+)b Unadjusted non-parametric
Kolmogorov–Smirnov testb,c: P, 0.025
Gao et al.25 106 (2)d; 35 (+) miR-145 (2) miR-145 (2) Multivariate linear regressione:
P, 0.008
Widera
et al.35
131 (2); 196 (+) miR-1, miR-133a/b, miR-208a/b,
miR-499
miR-133a (2); miR-208a (+) Unadjusted Mann–Whitey U testa:
miR-133a (P, 0.001);
miR-208a (P, 0.001)
Zhang R
et al.39
45 (2); 65 (+) miR-150, miR-486 miR-150, miR-486 (+) Unadjusted independent sample t-tests or
Mann–Whitney U testa: miR-150 (P ¼ 0.016);
miR-486 (P ¼ 0.015)
Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.
Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified
for each study separately.
aPatient characteristics: significant differences between these groups not presented/reported.
bPotentially confounded by extent of coronary stenosis; significant differences between patient groups only for pain onset and hs-TnTmax, not for other characteristics listed in Table 1.
cROC AUC values are also available in the SF2 Study Quality table.
dUA and non-STEMI combined.
eAdjusted for traditional risk factors.
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online, Table S3 gives an overview of all significant RNA targets for
which data validated by reporter assay analysis, qPCR, and western
blot analysis were available. Table 7 summarizes RNA targets which
are shared between at least two miR families.
We searched for common targets between these miRs. ETS proto-
oncogene 1, transcription factor (ETS1), involved in stem cell develop-
ment, cell senescence, and death, and tumour development was shared
between miR-1, miR-145, miR-208, and miR-499. It is implicated regu-
lation of platelet-derived growth factor receptor-alpha gene transcrip-
tion in VSMCs.120
miR-1 andmiR-133 shared 4 RNA targets: hyperpolarization-activated
cyclic nucleotide-gated potassium channel 4 (HCN4), LIM and SH3 pro-
tein 1 (LASP1), purine nucleoside phosphorylase (PNP), and transgelin 2
(TAGLN2). HCN4 channels regulate pacemaker activity.121,122 An in-
crease in HCN (HCN2 and HCN4) channel activity in hypertrophied
myocytes prolonged the re-polarization of the ventricular action poten-
tial, possibly linking an up-regulation of ventricular depolarizing current
I( f ) and a diminished re-polarization reserve in cardiac hypertrophy.123
The association between the chemokine receptors and LASP-1 is crucial
for regulation of migration of inflammation cells.124 PNP is crucial under
energy-deprived conditions for the cell to metabolize adenosine during
ATPdegradation and as such for regulation growth of activated T cells.125
miR-133a was found to directly bind to the 3′ UTR of TAGLN2 mRNA
and thereby suppressed expression at both transcriptional and transla-
tional levels, affecting differentiation of smooth muscle cells. Next,
TAGLN2 knockout was used to reveal that TAGLN2 modulated
hypoxia-induced apoptosis via caspase-8 apoptotic pathway.126
miR-133 shares two other RNA targets with miR-145: fascin actin-
bundling protein 1 (FSCN1) and insulin-like growth factor 1 receptor
(IGF1R). FSCN1 plays a critical role in cell migration, motility, adhesion,
and cellular interactions. Several studies have shown that the inter-
action of miR-145 and miR-133 with FSCN1 is crucial to inhibit migra-
tion and invasion of cancer cells.127–129 To our knowledge, it has not
yet been associated with atherosclerosis and cardiovascular diseases.
Reduction of miR-133a expression was associated with lower IGF1R
levels and suppression of VSMC growth through modulation of the
Akt/FOXO3a pathway.130,131 The antidiabetic hormone glucagon-like
peptide-1 induced formation of new elastic fibres in human cardiac fi-
broblasts after cross-activation of IGF1R, possibly contributing to bene-
ficial remodelling of the human heart after MI.132
Finally, miR-145 and miR-208 target cyclin-dependent kinase inhibi-
tor 1A (CDKN1A; or p21 or p21Cp1), a regulator of cell cycle
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Table 5 Overview of significant miRs identified in all included studies, organized by disease progression: survival vs. death
Study Number of
patients
Tested miRs Significant miRs Statistical analysis
Devaux et al.22 1053 (2); 102(+)a miR-133a, miR-208b, miR-223, miR-320a,
miR-451, miR-499
miR-208b (+) Unadjusted ROC (AUC: 95% CI)a:
0.67: 0.52–0.81
Dong et al.23 224(2); 22(+)b miR-145 miR-145 (+) Multivariate Cox regression
(HR: 95% CI)b,c:
5.63: 1.99–15.91, P ¼ 0.0012
Goretti et al.27 446(2); 64(+)d miR-208b, miR-499 – Multivariate linear regressiond: ORs and 95%CI
include 1
He et al.28 276 (2); 83 (+)e miR-134, miR-328 miR-134, miR-328 (+) Multivariate logistic regression (OR: 95% CI)e:
miR-134 (2.28: 1.03–11.32, P ¼ 0.013);
miR-328 (7.35: 1.07–17.83, P ¼ 0.004)
Matsumoto
et al.30
21(2); 19(+)f miR-18a, miR-93, miR-125a-5p, miR-134,
miR-155, miR-190b, miR-192, miR-212,
miR-223, miR-331-3p, miR-380
miR-155 (+), miR-380 Mann–Whitney U testf; P, 0.05
Widera et al.35 410 (2); 34 (+)g miR-1, miR-133a/b, miR-208a/b, miR-451,
miR-499
miR-133a, miR-208b (+) Multivariate Cox regression (HR: 95% CI)g,c:
miR-133a (3.5: 1.8–7.0, P ¼ 0.001);
miR-208b (2.7: 1.4–5.3, P ¼ 0.006)
Zampetaki
et al.36
21 (2); 26 (+)h miR-7b/e, miR-21, miR-24, miR-25,
miR-28-3p, miR-93, miR-122, miR-126,
miR-140, miR-146b, miR-150, miR-191,
miR-197, miR-223, miR-320, miR-342-3p,
miR-454, miR-486
miR-126 (+); miR-223 (2) Multivariate Cox regression (HR: 95% CI)h:
miR-126 (2.70: 1.21–6.05, P ¼ 0.016);
miR-223 (0.37: 0.2–0.7, P ¼ 0.002)
Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.
Traditional risk factors: age, gender, body mass index, diabetes, hypertension, dyslipidemia, smoking; blood levels of glucose and/or lipids; other blood markers and medication as specified
for each study separately.
aAll-cause 30-day mortality; patient characteristics: significant differences between these groups not presented/reported; no miRs significantly predicted mortality when univariate Cox
proportional hazard analysis undertaken
bCardiac death at 1 year; hazard regression analysis adjusted for age, circulating miR-145, cTnI, CK-MB, LVEF, eGFR, and NT-proBNP.
cROC AUC values are also available in the SF2 Study Quality table.
dAMI only 6-year mortality, adjusted for traditional risk factors.
eHeart failure or cardiogenic death within 6 months combined, adjusted for age, gender, current smoking, hs-cTnT, NTproBNP, and time from AMI onset to sampling.
fCardiac death at 1-year post-hospital discharge following MI; to adjust for confounding patients were selected from larger cohort using propensity score by logistic regression of traditional
risk factors and previous MI, Killip class at admission, infarct size, reperfusion therapy, and medication at discharge.
gAll-cause 6-month mortality; significant difference in survival adjusted for age and gender. However, no significant miRs remained when Cox regression analysis included hsTnT.
hNon-fatal vs. fatal MI within 10 years of study; adjusted for traditional risk factors and CVD history, other miRs; potentially confounded by death occurring in first vs. last 5 years for
miR-126.
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progression at G1. Gene silencing studies demonstrated that disturbed
flow induced endothelial cell senescence via a p53–p21 signalling path-
way, resulting in reduced migration, and thus may be defective for ar-
terial repair.133 The microRNA-155/FOXO3a signalling pathway and
induction of induction of FOXO3a targets, p21 and p27(kip1), have
been implied in global remodelling of the vascular stem cell niche in
bone marrow of diabetic patients.134
4. Discussion
Our review identified miR-1, miR-133a/b, miR-145, miR-208a/b, and
miR-499(a) as the most promising miR biomarkers and/or prognostic
markers for progressing stages of cardiovascular disease. Interestingly
4 of those miRs (miR-1, miR-133, miR-208, and miR-499) were found
to control cardiomyocyte identity.118 In addition, they share several
other functions such as regulation of endothelial function and angiogen-
esis (miR-1, miR-133), VSMC differentiation (miR-133, miR-145), com-
munication between vascular smooth muscle and endothelial cell to
stabilize plaques (miR-145), and apoptosis (miR-1, miR-133,
miR-499), which are crucial processes in the pathogenesis of cardiovas-
cular disease. Finally, we identified shared RNA targets linking them to
common functions. These functions further support their clinical rele-
vance as diagnostic markers.
Although 19 studies were included in the review, no meta-analysis
was undertaken due to the heterogeneity of the studies, including
the differences across miRs and diseases studied, and also because of
important differences and limitations in study design including: clinical
settings, population characteristics, sample collection and handling,
and qPCR normalization methods. These limitations led the research
team to provide an overview of the limitations and highlight examples
of good practice identified in this review, to inform future research on
the methods to consider when undertaking and reporting properly de-
signed miR biomarker studies.
4.1 Participant characteristics and
comparison groups
Proper comparison groups are needed to be able to make a differential
diagnosis. Comparing patients with disease to healthy controls has
been shown to overestimate the accuracy of the diagnostic test,19
and in practice, clinicians are assessing and comparing patients with
chest pain/disease and so need a diagnostic tool that will more accur-
ately distinguish between diseased patients. Most studies that were ex-
cluded from the analysis compared patients with healthy controls and
did not adjust for differences in metabolic profiles of patients and
healthy controls, increasing the likelihood of obtaining more significant
differences in miR expression between patients and controls but with-
out adding clinical value in discriminating between patients who present
with similar symptoms and metabolic profiles. Since diagnostic studies
are not often able to be designed as randomized clinical trials, it is im-
portant for these studies to provide clear phenotyping of patients with
known potential confounders and risk factors for disease.
Too often, adjustment for comorbidities and medication is lack-
ing.135 However, information on medication is crucial in view of a re-
cent discovery that miRs determine the efficacy of drugs, which has
given rise to the field of ‘miRNA pharmacogenomics’ through
‘Pharmaco-miRs’. Indeed, miRs play a significant role in pharmacogen-
omics by down-regulating genes that are important for drug func-
tion.136 In addition, medication affects miR expression. Statins were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Overview of significant miRs identified in all included studies, organized by disease progression: cardiovascular disease
progression
miRa CAD ACS AMI STEMI Mortality Study reference
miR-1 No24 +31 +34,35 No24 No35 24,31,34,35
miR-21 2 +31 No36 2 No36 31,36
miR-122 No24;
+26
2 No36 No24 No36 24,26,36
miR-126 No32 2 + 36 2 +36 32,36
miR-133a/b +24,33 2 No22;
+34,35
No24;
+22,35
No22;
+35
22,24,33–35
miR-134 +24 2 2 +24 No30;
+28
24,28,30
miR-145 +25 +25 2 +25 +23 23,25
miR-146a/b 2 +31 No36 2 No36 31,36
miR-150 2 +37 No36 +39 No36 36,37,39
miR-208a/b No24 +31 +22,34,35 No24;
+22,35
No27;
+22,35
22,24,27,31,34,35
miR-320(a) 2 2 No36;
+22
No22 No22,36 22,36
miR-486 2 2 No36 +39 No36 36,39
miR-499(a) No24 +31 No35;
+22,34,38
No24,35;
+22
No22,27,35 22,24,27,31,34,35,38
Patient numbers and the direction of regulation of significant miRs (in parentheses) are ordered from less to more severe disease.
amiRs were only included in this table if theywere studied in at least two different studies and across at least two areas of disease progression. miRs presented have been reported as having a
significant difference in miR expression (+) or no difference in miR expression (No) between patients compared in the studies, with each study reference number included as a subscript.
However, miR-16 and miR-223 were not added since no studies reported a significant difference of miR expression between patient groups.
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Figure 2 Function of miRs. We identified miR-1, miR-133, miR-145, miR-208, and miR-499 as significant diagnostic and/or prognostic markers across
different cardiovascular disease progression stages. They regulate endothelial function and angiogenesis (miR-1, miR-133), VSMC differentiation
(miR-133, miR-145), communication between vascular smooth muscle and endothelial cell to stabilize plaques (miR-145), and regulate apoptosis in
endothelial and VSMCs (miR-1, miR-133, miR-499), cardiac myocyte differentiation (miR-1, miR-133, miR-145, miR-208, miR-499), and repress cardiac
hypertrophy (miR-133).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 7 Overview of RNA targets shared by at least two miR families
CDKN1A ETS1 FSCN1 HCN4 IGF1R LASP1 PNP TAGLN2
miR-1-3p Y Y Y Y Y
miR-133a-3p Y Y Y Y
miR-133b Y Y Y
miR-145-5p Y Y Y Y
miR-208a-3p Y Y
miR-208b-3p Y
miR-499a-5p Y
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found to change the expressions of 22 whole bloodmiRs and 19 plasma
miRs.137 Willeit and Zampetaki et al.138 found that plasma levels of
platelet miRs, such as miR-223 and miR-191, and others, such as
miR-126 and miR-150, decreased on platelet inhibition. It has also
been shown that heparin can alter miRs in plasma, and therefore blood
samples should be collected prior to heparin administration.139
As the topic of miR in cardiology is still new and the technology is
expensive, several selected studies enrolled small numbers of subjects,
also limiting the generalizability of the findings.
4.2 Sample collection and handling
Divergence between studies may also be due to differences in sample
collection and handling. However, sufficient information to reproduce
and ensure high-quality sample collection and handling is often scarce in
publications. In all steps when collecting whole blood, measures should
be taken to prevent contamination with mi(RNA) from intact cells and
to prevent haemolysis. Hence, we recommend the National Cancer In-
stitute’s Early Detection Research Network standard operating proce-
dures for the collection of serum and plasma.140 The whole blood
should be processed immediately. In the preparation of plasma, antic-
oagulants such as EDTA and citrate should be used. Heparin should be
avoided because it is known to inhibit cDNA synthesis and PCR.141
Haemolysis should be screened by measuring oxyhaemoglobin absorb-
ance at 414 nm.142 Once prepared and before freezing, plasma or ser-
um should be centrifuged for 5 min at 3000 g to remove cells.
4.3 qPCR normalization methods
Divergence between studies may also be due to differences in qPCR
normalization methods. These methods rely on two standard assump-
tions: (i) the majority of features do not vary between samples, and (ii)
the proportions of up- and down-regulated expressions are approxi-
mately equal. To compensate for the lack of robustness in the existing
methods, the least-variant set (LVS) normalization for mRNA arrays
was developed based on data-driven housekeeping genes.143 For nor-
malization of miR data, one can (i) identify and use several stably ex-
pressed reference miRs, or even better (ii) use the global mean
expression value of all commonly expressed miRs in a given sample
as normalization factor.144–147 However, only one study included in
this review presented the reference miR expression levels—visually
confirming that the level of the reference miR did not change between
comparison groups.33 One should avoid using larger small RNA species
such as U6 because they have a different biogenesis pathway and may
not be secreted or protected in biofluids in the same way as miRs
are.148,149 Furthermore, the use of exogenous spike-in controls to ob-
tain standardized normalization has been considered, with seven of the
included studies in this review also using an exogenous spiked in miR
reference (see the SF2 Study Quality table). Recently, Roberts
et al.150 compared the use of different normalization strategies for
the quantification of extracellular miRs in mouse serum. The levels of
the putative endogenous miRs were positively correlated with the ex-
ternal spike-in control, indicating that variations in the latter reflect
changes in endogenous miR abundance. Furthermore, the external
spike-in control was the least variable miR across all samples in the
RT-qPCR array study, and between experimental groups in the time
course study thus validating this normalization approach. Additionally,
more miRs were statistically significant, and greater fold changes ob-
served, when the data were normalized to the spike-in control as op-
posed to the average Cq. The ratio of up- and down-regulated miRs
was more balanced when the data were normalized to the average
Cq. But, the observation of a global shift in miR levels suggests that
this ‘balance’ may be artificial.150 Several companies (e.g. Exiqon)
have developed a set of synthetic spike-in RNAs which can be used
to monitor the efficiency of RNA isolation, cDNA synthesis, and
PCR amplification and to reveal potential presence of nucleases.
4.4 Selection of miRs
For this systematic review, we were only able to access data which are
available in the public domain151; it is possible that other miRs were
measured in the studies and were not reported, which is supported
by the reporting of nine included studies that only present data on
one or two miRs. It is also possible that other miRs studies with nega-
tive results were not published at all, adding to the potential bias in
identifying miRs with the best potential to support diagnosis or progno-
sis of cardiovascular disease. There is also inherent bias in the selection
of the miRs studied, as the field is still developing, only few of the known
miRs have been studied. In all but four cases in the included studies, the
decision was made on insights from the previous literature, so few stud-
ies have used array technology to screen vast numbers of miRs and usu-
ally have done so for a very small number of participants. Because there
are so many potential miRs to study, only a few studies have replicated
similar combinations of miRs in comparable cohorts. In this review,
miR-1, miR-133a/b, miR-208a/b, and miR-499(a) were studied in four
or more separate studies but across different disease comparison
groups and with contrasting results. Although we excluded case-
control studies for reasons explained above, we want to acknowledge
the importance of the pioneer studies because they have been driving
miR selection. In particular, miR-1,67,68,77,82 eventually in combination
with miR-133 and miR-499,70 and miR-133, miR-208, and miR-499
have been studied extensively.66,69,72,88,91
Several studies24,31,37 also suggested that the diagnostic values of
clusters of miRs may be higher than that of any single miR. However,
cluster analysis does not provide information as to how a certain miR
cluster would translate into pathogenesis or altered cellular functions
in the investigated pathology.
Our approach of collating several studies allowed us to provide a list
of potentially useful miRs for diagnosis of cardiovascular disease; how-
ever, a self-selection bias that arises from scientific trends to investigate
similar or same hot-spot miRs by several groups cannot be excluded.
Nevertheless, we conclude that such assumptions are inherently pre-
sent in any secondary literature study and regard it as a benefit of
our review process to make these assumptions explicit and traceable.
To prevent selective publication and selective reporting of miR re-
search outcomes, data-sharing plans are needed, as recently proposed
by the International Committee of Medical Journal Editors.152 Sharing
data will increase confidence and trust in the conclusions drawn from
clinical studies. It will enable the independent confirmation of results,
an essential tenet of the scientific process. It may also make progress
more efficient by avoiding unwanted repetition in case of reporting
high-quality negative results.
4.5 Mirs in cells or tissues
In our review, we focused on miRs in plasma and serum and miRs ex-
amined in cells or tissues other than blood were excluded. Indeed, sev-
eral miR-based studies have utilized tissues/cells for identifying miRs.
But tissues other than blood (and eventually urine) are much less ac-
cessible and therefore less useful for biomarker analysis. In addition,
several of our identified miRs are claimed to have tissue specificity.
miR-1 is the most abundant miR specific for cardiac and skeletal muscle
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and functions as a regulator of differentiation and proliferation during
cardiogenesis153 as well as a regulator of cardiomyocyte growth in
the adult heart. In human hearts of patients who had died of MI,
miR-1 was up-regulated in remote myocardium when compared with
infarcted tissue or healthy adult heart.154 Adachi et al. performed a miR
array analysis in various human tissues to identify heart-specific miRs
and found miR-499 almost specifically expressed in the heart, conclud-
ing that miR-499 might serve as an additional promising biomarker of
MI.58,66 miR-133, which is transcribed from the same chromosomal
loci as miR-1, enhances myoblast proliferation and thus is involved in
cardiomyocyte proliferations.155 As shown in a mouse model,
miR-208 is exclusively expressed in cardiomyocytes and consequently
released during cardiomyocyte death in MI.156 Two other miRs which
were identified in some studies were miR-21 and miR-126. miR-21 is
up-regulated in cardiomyocytes shortly after initiation of ischaemia.
However, increased expression of miR-21 in fibroblasts enhances their
proliferation,157 suggesting a role of miR-21 in remodelling.158 Levels of
miR-126 were up-regulated in the non-infracted areas after induced MI
in rat hearts. The effect of ischaemia reperfusion on miRs in the rat
heart was evaluated by Tang et al.159 The authors found that levels of
miR-1, miR-126, and miR-208 were increased, while miR-21, miR-133,
and miR-195 levels had decreased. Finally, we did not identify miR-29,
although members of the miR-29 family were down-regulated in the re-
gion adjacent to MI areas in mice and humans.160
As stated earlier, miRs in plasma avoid degradation by being packaged
in microvesicles (exosomes, microvesicles, and apoptotic bodies) or by
being bound with proteins or HDLs.161 In inflammatory microvesicles,
miR-133 was among the most interesting miRs in association with meta-
bolic and cardiovascular diseases, together with the let-7 family, miR-17/
92 family, miR-21, miR-29, miR-126, miR-133, miR-146, and miR-155.14
OthermiRs were also identified as potential markers in plasma or serum,
such as miR-126 predicted the occurrence of cardiovascular events in
patients with stable CAD.51 Independent study revealed a significant re-
duction of miR-126 expression in circulating microvesicles in patients
with stable CAD with and without diabetes mellitus.162 A group of
miRs, including miR-21 and miR-126, were up-regulated in microvesicles
isolated from the plasma of UA patients compared with controls.11 In
addition, miRs control the expression of most of the genes associated
with HDL metabolism, including the ATP transporters, ABCA1, SRB1,
etc. These findings suggest that miRs regulate HDL biogenesis, cellular
cholesterol efflux, and HDL cholesterol uptake in the liver, thereby con-
trolling all of the steps of reverse cholesterol transport, likely to be asso-
ciated with cardiovascular disease.163 For example, expression of
ABCA1, associated with HDL, is highly regulated at the post-
transcriptional level by multiple miRs, including miR-145. miRs also regu-
late the expression of LXR (liver X receptors), thereby controlling the
transcriptional activation of ABCA1. LXR is directly targeted by miR-1
together with miR-206, miR-613, and miR-155.164 In addition, HDL
can transport miRs and deliver them to the receiving cells influencing
their gene expression. Hence, it has been suggested that future studies
should include data onmiR expression in HDL particles ormicrovesicles.
However, requirement of a high volume of plasma to isolate HDL and/or
microvesicles and the current time consuming and expensive extraction
procedures render such studies very unlikely, at least in the near future.
Nevertheless, as seen in the studies included in this review, little or no
information about presence in solution or package in HDL or micropar-
ticles was disclosed. Therefore, these data warrant further investigation
of the potential of microvesicles as putative biomarkers and as novel car-
riers for the cell-specific transfer of miRs and other therapeutic agents.
4.6 Prognostic research
Further research is required and should concentrate on determining
the prognostic value of miR deregulations before the onset of clinical
cardiovascular symptoms. All studies in this review, except one, deter-
mined the association of miRs with the cardiovascular disease state at
the time of blood sampling, and because of lack of follow-up of the pa-
tients, did not determine prognostic value of miRs to identify new
events in addition to other risk factors. In order to do that, large-scale
studies with longer patient follow-up periods are needed. This is where
blood samples collected in biobanks could be useful as they represent
both healthy and diseased populations. As blood samples in biobanks
were collected with no particular goal initially, a majority of them are
not suitable for detection of miRs other than in plasma or serum.
In conclusion, we reviewed the deregulated circulating miRs which
may be useful for futuremiR research using blood samples from biobanks
worldwide. We applied a systematic review approach to identify miRs
which are more likely to be associated with CVD. Finally, we identified
major limitations in current miR research and provided an overview of
several aspects researchers should consider to prepare the highest-
quality future studies and publications possible. Certainly, large-scale
and standardized (references, adjustment for established cardiovascular
and metabolic factors and medications) follow-up studies are needed
to establish the prognostic value of miRs. Summarizing the most promis-
ing miRs, also by linking them to target genes implied in the development
of CVD, could also be helpful in designing these future studies.
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